CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

Jay Backstrom; President, Chief Executive Officer, Director; Scholar Rock Holding Corp Tracey Sacco ... We will also be sharing our work with the murine version of a apitegromab in a non-clinical ...

Shares in Scholar Rock have gone into overdrive after the biotech ... which is designed to work directly on the muscles in SMA, binding pro- and latent forms of myostatin to bolster muscle ...

This announcement is based on a press release statement from Scholar Rock. The company is known for its work in developing therapies for diseases with high unmet need, leveraging its proprietary ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The firm has a 50 day simple moving average of $41.89 and a 200 day simple moving average of $28.17. Get Scholar Rock alerts: ...

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug Future of Healthcategory· November 20, 2024 Scholar Rock's experimental drug achieved its main target in a ...

CAMBRIDGE, Mass., February 14, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular ...